Retatrutide Brand Name: What Will It Be Called?

Retatrutide Brand Name: What Will It Be Called?

Eli Lilly has not announced a brand name for retatrutide. The drug is still in Phase 3 clinical trials and is identified only by its generic name (retatrutide) and development code (LY3437943). A brand name will likely be revealed close to FDA approval, which is projected for Q3-Q4 2027.

When Will the Brand Name Be Announced?

Brand names are typically revealed at or near the time of FDA approval — not during clinical trials. The naming process begins years in advance, but the public announcement only comes after:

  1. Phase 3 trials are successfully completed
  2. The NDA (New Drug Application) is submitted to the FDA
  3. The FDA reviews the data (typically 10-12 months)
  4. The proprietary name clears the FDA's safety review (checking it won't be confused with other drug names)

For retatrutide, the NDA is expected in Q4 2026, with FDA approval projected for Q3-Q4 2027. The brand name could be announced anywhere from late 2026 to mid 2027.

How Drug Brand Names Are Created

A pharmaceutical drug has three layers of naming:

Generic Name (retatrutide)

Assigned through the USAN (United States Adopted Names) Council and the WHO's INN (International Nonproprietary Name) program. Generic names follow strict conventions with stems that indicate a drug's pharmacologic family. The name consists of:

  • Prefix: meaningless differentiator ("reta-")
  • Infix: further subclassification ("-tru-", likely from "triple")
  • Stem: indicates drug family ("-tide" = peptide)

Brand Name (TBD)

Chosen by the pharmaceutical company, typically with help from specialized naming agencies. Must pass the FDA's Division of Medication Error Prevention and Analysis review, which evaluates whether the name could be confused with existing drugs in handwritten or spoken form. Must also be available as a global trademark.

Development Code (LY3437943)

Internal identifier used during research. "LY" is Eli Lilly's standard prefix.

Lilly's Naming Pattern

Eli Lilly has established a precedent of using different brand names for different indications of the same molecule:

Generic NameDiabetes BrandObesity BrandOther
TirzepatideMounjaroZepbound—
DulaglutideTrulicity——
RetatrutideTBDTBDPossibly MASH/NAFLD brand too

This follows Novo Nordisk's playbook (Ozempic for diabetes vs Wegovy for obesity — both semaglutide). It is likely that Lilly will give retatrutide at least two brand names — one for obesity and one for type 2 diabetes — if approved for both indications.

What the Existing Names Tell Us

  • Mounjaro — evokes "climbing Kilimanjaro," a great accomplishment
  • Zepbound — aurally suggests "zap pound." Lilly's president of Diabetes and Obesity said it "tested very well with consumers and healthcare professionals"
  • Wegovy — suggests "we go," a "we're in this together" mindset
  • Ozempic — evokes "Olympic" and peak fitness

Pharmaceutical branding agencies test hundreds of candidate names with consumers and healthcare professionals before selecting a final name.

The -tide Suffix Explained

The -tide stem in drug naming indicates a peptide or modified peptide. The evolution of GLP-1 drug stems tracks the evolution of the mechanism:

DrugStemMeaningReceptors
Semaglutide, liraglutide, dulaglutide-glutideGLP-1 related peptideGLP-1 only
Tirzepatide-patideGIP-related peptideGLP-1 + GIP
Retatrutide-trutideTriple agonist peptideGLP-1 + GIP + Glucagon

The "-tru-" infix in retatrutide likely derives from "triple," reflecting that this is a distinct sub-class of triple-receptor agonist peptides. Each new stem signals to clinicians that the drug belongs to a progressively broader class of receptor activity.

Drug vs Biologic Classification

In September 2024, Eli Lilly sued the FDA challenging the classification of retatrutide as a "drug" rather than a "biological product." Retatrutide has 39 amino acids — just one short of the FDA's 40-amino-acid threshold for classification as a "protein" (and therefore a biologic).

This classification matters for:

  • Marketing exclusivity — biologics receive 12 years of exclusivity vs 5 years for small-molecule drugs
  • Compounding rules — drugs can be compounded by pharmacies more easily than biologics
  • Regulatory pathway — a Biologics License Application (BLA) rather than an NDA

If Lilly wins, retatrutide would be filed as a biologic, which could affect naming suffix conventions and market protection — but not the brand name itself.

Frequently Asked Questions

What is the brand name for retatrutide?

There is no brand name yet. Eli Lilly has not announced one. The drug is currently identified only as "retatrutide" (generic name) or LY3437943 (development code).

When will the brand name be announced?

Likely in late 2026 or 2027, around the time of NDA submission or FDA approval.

Will retatrutide have multiple brand names?

Probably. Lilly uses separate brand names for separate indications (Mounjaro for diabetes, Zepbound for obesity — both tirzepatide). Retatrutide will likely have at least two brand names if approved for both obesity and type 2 diabetes.

Is "GLP-3" a brand name?

No. "GLP-3" is an informal nickname used by patients and media to describe retatrutide as the next generation after GLP-1 drugs. It is not an official pharmaceutical name. See GLP-1 vs GLP-2 vs GLP-3 for the full explanation.

Sources

  • MedExpress. (2026). Retatrutide: Everything You Need to Know. Link.
  • Real Peptides. (2025). What Is the Brand Name for Retatrutide? Link.
  • Catchword Branding / STAT News. (2023). What Eli Lilly's Zepbound Reveals About the Intricate Process of Naming Drugs Today. Link.
  • Big Molecule Watch / Goodwin Law. (2024). Eli Lilly Files Suit Challenging the FDA's Drug Classification of Retatrutide. Link.

Medical Disclaimer

The content on glp3.wiki is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Retatrutide is an investigational drug that has not been approved by the FDA.

This site is not affiliated with Eli Lilly and Company or any pharmaceutical manufacturer.